alfatide
Small moleculeexperimentalImaging agent
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Jan 1, 2012 (NCT02441972)
Timeline
Indications
Mechanism of action
- Vitronectin receptor alphaBINDING AGENT
ITGAV binding agent
Chemistry & pharmacology
- Imaging
- 18-fluorine
Oral
No
Parenteral
No
Topical
No
Also known as
- 18f-alfatide
- 18f-alfatide ii
- 18f-alfatide ii
- 18f-alf-nota-e(peg4-c(rgdfk))2
- 18f-alf-nota-prgd2
- 18f-al-nota-prgd2
- 18f-al-nota-prgd2
- alfatide
- alfatide ii
- alfatide ii
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06416852 | Phase 3 | Aug 31, 2024 | Yantai LNC Biotechnology Singapore PTE. LTD. |
| NCT02582801 | Phase 1 | Oct 1, 2015 | Jinlin University |
| NCT02481726 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2014 | People's Liberation Army of China |
| NCT02441972 | Phase 1 | Jan 1, 2012 | Wuxi No. 4 People's Hospital |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Jinlin University | Academic/Hospital | 1 | 1 | 1 | 2015 |
| People's Liberation Army of China | Government | 1 | 1 | 1 | 2014 |
| Wuxi No. 4 People's Hospital | Academic/Hospital | 1 | 1 | 1 | 2012 |
| Yantai LNC Biotechnology Singapore PTE. LTD. | For profit | 1 | 1 | 1 | 2024 |
4 organizations
Page 1 / 1